GBT Announces Participation in Upcoming Investor Conferences
Global Blood Therapeutics (GBT) announced its participation in virtual investor conferences on March 7 and March 16, 2022. CEO Ted W. Love will engage in a panel discussion on non-malignant hematology at the Cowen 42nd Annual Health Care Conference. Both events will be webcast live on GBT’s website, with replays available for one month.
GBT focuses on developing treatments for sickle cell disease (SCD), including Oxbryta®, the first FDA-approved treatment targeting the root cause of SCD.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in virtual fireside chats at the following investor conferences:
- Cowen 42nd Annual Health Care Conference on March 7, at 2:10 p.m. E.T.; and
- Oppenheimer 32nd Annual Healthcare Conference on March 16, at 2:40 p.m. E.T.
Ted W. Love, M.D., president and chief executive officer of GBT, will also participate in a virtual panel, Non-Malignant Hematology, at the Cowen conference on March 7, at 12:50 p.m. E.T.
The fireside chats and panel will be webcast live from GBT’s website at www.gbt.com in the Investors section. Replays of the webcasts will be archived and available for one month following each event.
About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor), the first FDA-approved medicine that directly inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase 3 development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next generation HbS polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Contact:
Steven Immergut (media)
650-410-3258
simmergut@gbt.com
Courtney Roberts (investors)
650-351-7881
croberts@gbt.com
FAQ
What dates is GBT participating in investor conferences?
Who will represent GBT at the conferences?
What is Oxbryta® related to GBT?
Where can I watch GBT's conference webcasts?
What is the focus of GBT's development programs?
